These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 100564)

  • 1. Tissue-reacting antibodies (EVI antibodies) in nifurtimox-treated patients with Chagas's disease.
    Schmuñis GA; Cossio PM; Szarfman A; Coarasa L; Arana RM
    J Infect Dis; 1978 Sep; 138(3):401-4. PubMed ID: 100564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EVI antibodies in patients with Chagas' disease: relationship with anti-Trypanosoma cruzi immunoglobulins and effects of specific treatment.
    Brener Z; Ramirez LE; Krettli AU; Cançado JR
    Mem Inst Oswaldo Cruz; 1983; 78(4):437-42. PubMed ID: 6443630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of antibody dependent cytotoxicity to Trypanosoma cruzi in chronic chagasic mice after treatment with nifurtimox.
    Chambó JG; Cabeza Meckert PM; Laguens RP
    Medicina (B Aires); 1988; 48(1):49-53. PubMed ID: 3146009
    [No Abstract]   [Full Text] [Related]  

  • 4. Investigation of the EVI antibody in parasitic diseases other than American trypanosomiasis. An anti-skeletal muscle antibody in leishmaniasis.
    Szarfman A; Khoury EL; Cossio PM; Arana RM; Kagan IG
    Am J Trop Med Hyg; 1975 Jan; 24(1):19-24. PubMed ID: 1089366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in resistance to reinfection with low and high inocula of Trypanosoma cruzi in chagasic mice treated with nifurtimox and relation to immune response.
    Cabeza Meckert P; Chambó JG; Laguens RP
    Antimicrob Agents Chemother; 1988 Feb; 32(2):241-5. PubMed ID: 3129986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental production of EVI antibodies.
    Lenzi HL; Lenzi JG; Andrade ZA
    Am J Trop Med Hyg; 1982 Jan; 31(1):48-52. PubMed ID: 7036770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoglobulin concentration in treated human acute Chagas disease. A follow-up study.
    Schmuñis GA; Szarfman A; Coarasa L; Vainstok C
    Am J Trop Med Hyg; 1978 May; 27(3):473-7. PubMed ID: 98063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
    Cabrera E; Murguiondo MG; Arias MG; Arredondo C; Pintos C; Aguirre G; Fernández M; Basmadjián Y; Rosa R; Pacheco JP; Raymondo S; Di Maio R; González M; Cerecetto H
    Eur J Med Chem; 2009 Oct; 44(10):3909-14. PubMed ID: 19446929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of the efficacy of nifurtimox in chronic human chagasic infection by using xenodiagnosis (author's transl)].
    Cerisola JA; Neves da Silva N; Prata A; Schenone H; Rohwedder R
    Bol Chil Parasitol; 1977; 32(3-4):51-62. PubMed ID: 416834
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of length of treatment with Bayer 2502 on isolation of Trypanosoma cruzi and resistance to challenge in the mouse.
    Morrow DT; Wescott RB; Davis WC
    Am J Trop Med Hyg; 1977 May; 26(3):382-6. PubMed ID: 405877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of Chagas' disease with nifurtimox during the first months of life].
    Moya PR; Paolasso RD; Blanco S; Lapasset M; Sanmartino C; Basso B; Moretti E; Cura D
    Medicina (B Aires); 1985; 45(5):553-8. PubMed ID: 3939553
    [No Abstract]   [Full Text] [Related]  

  • 12. [Etiologic therapy of Chagas' disease].
    Boainain E; Rassi A
    Arq Bras Cardiol; 1979 Jun; 32(6):395-9. PubMed ID: 116629
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunofluorescent vascular pattern due to EVI antibody of Chagas' disease. Its diagnostic value.
    Khoury EL; Cossio PM; Szarfman A; Marcos JC; García Morteo O; Arana RM
    Am J Clin Pathol; 1978 Jan; 69(1):62-5. PubMed ID: 413431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Etiological treatment of Chagas' disease].
    Rassi A
    Arq Bras Cardiol; 1982 Apr; 38(4):277-81. PubMed ID: 6820273
    [No Abstract]   [Full Text] [Related]  

  • 15. Follow-up of an asymptomatic Chagas disease population of children after treatment with nifurtimox (Lampit) in a sylvatic endemic transmission area of Colombia.
    Bianchi F; Cucunubá Z; Guhl F; González NL; Freilij H; Nicholls RS; Ramírez JD; Montilla M; Flórez AC; Rosas F; Saavedra V; Silva N
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003465. PubMed ID: 25723465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types.
    Andrade SG; Magalhães JB; Pontes AL
    Bull World Health Organ; 1985; 63(4):721-6. PubMed ID: 3936634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Changes in parasitemia evaluated using the modified Strout method in patients with acute Chagas disease under treatment].
    Castro C; Emanuel A
    Rev Soc Bras Med Trop; 1988; 21(4):177-80. PubMed ID: 3152133
    [No Abstract]   [Full Text] [Related]  

  • 18. Tissue reacting antibodies in a rhesus monkey with long-term Trypanosoma cruzi infection.
    Szarfman A; Laranja FS; de Souza W; Galvão Quintao L; Gerecht D; Schmuñis GA
    Am J Trop Med Hyg; 1978 Jul; 27(4):832-4. PubMed ID: 99060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined treatment with a nitrofuranic and a corticoid in experimental Chagas' disease in the dog.
    Andrade SG; Andrade ZA; Sadigursky M
    Am J Trop Med Hyg; 1980 Sep; 29(5):766-73. PubMed ID: 6776831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of Chagas' disease].
    Apt W
    Rev Med Chil; 1985 Feb; 113(2):162-6. PubMed ID: 3936147
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.